DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME

Abstract: This invention relates to a diamine derivative represented by the following formula (1) or a salt thereof. wherein R 1 represents H, OH, an aralkyloxy group or a halogen atom; R 2 represents H or a lower alkyl group; A represents -C(R 3 )=CH-, -CH=N-, -N(R 4 )-, R 3 being H or OH, R 4 being a lower alkyl group or an alkoxyalkyl group, -O-, or -S-; B represents a single bond, -C(R 5 )(R 6 )-(CH 2 )k-, R 5 and R 6 being H or a lower alkyl group, and k being a value of from 0 to 2, -S(O) q CH(R 7 ), or -CH=CH-; E represents a single bond or -(CH 2 ) 3 -; W and Y individually represent -CH 2 - or -CO-; Z represents O or S; and m is a value of 2 or 3, and n is a value of from 1 to 4; with the proviso that E is -(CH 2 ) 3 - when B is a single bond and E is a single bond when B is a group other than a single bond. The diamine derivatives or salts thereof have both antileukotrienic action and antihistaminic action and are low in brain penetration, and are hence useful as asthma preventives and curatives.

Description: Technical Field This invention relates to novel diamine derivatives having antihistaminic action and antileukotrienic action and also to medicines containing the same. Background Art An asthma treating agent containing a benzimidazole derivative is known from JP 0 959 158. JP 07 149 646 discloses isoquinolinesulfoneamide derivatives for the treatment of allergic diseases. Histamine exhibits bronchial smooth muscle constricting action and capillaropenetration accelerating action as a result of its binding to the H 1 receptor in cell membranes, and is considered to be an important mediator in allergic diseases. Described specifically, histamine is believed to cause aggravation of asthmatic symptoms by its bronchoconstricting action and also to increase transudation of blood components into intercellular spacings due to accelerated capillaropenetration and hence to take part in the formation of edema seen in allergic rhinitis and conjunctivitis. For the treatment of these allergic diseases, antihistaminic agents are therefore used. Conventional antihistaminic agents however bind to the H 1 receptor in the brain, so that side effects on the central nerve system, such as drowsiness, are concerned. In recent years, bronchial asthma is regarded as eosinophilic chronic inflammation of the airway, and a late asthmatic response that the symptom of airway constriction which is typical to asthma is developed due to infiltration of inflammatory cells on the bronchial mucosa, oversecretion of mucus and the like is at issue. Antihistaminic agents are not effective for such late asthmatic responses, leading to the existence of an outstanding desire for the development of pharmaceuticals of a new type for their treatment. Leukotrienes (LT) are associated with causes for most inflammatory diseases, especially asthma, psoriasis, rheumatism and inflammatory colitis, and are considered to play an important role in inflammatory processes through cytopathy. Leukotrienes are principal mediators of allergy and inflammation, and therefore many substances which inhibit the action and/or syntheses of leukotrienes are being discovered for the treatment of these diseases (S.T. Holgate et al.: J. Allergy Clin. Immunol., 98 , 1-13, 1996). Leukotrienes are arachidonate metabolites synthesized by 5-lipoxygenase (5-LO), and consist of two groups. One of the groups is LTB 4 and has strong chemotaxis towards leukocytes. The other group is collectively called cysteine leukotrienes (CysLT) and includes LTC 4 , LTD 4 and LTE 4 . As biologically active substances, they have been called "slow-reacting substances of anaphylaxis (SRS-A)" for many years. CysLT binds to their receptors in human tissues to exert its action. A selective LTD 4 receptor inhibitor has been found to inhibit contracting actions of both LTC 4 and LTD 4 in human lung tissues, so that LTC 4 is suggested to bind to the same site of a receptor as LTD 4 (Buckner C.K. et al: Ann. NY Acad. Sci., 524 , 181-6, 1988; Aharony D. et al.: New Trends in Lipid Mediators Research, Basel: Karger 67-71, 1989). LTE 4 is also considered to act via the same receptor as LTD 4 , but is called a partially active substance for its lower potency. Described specifically, in an allergic disease such as asthma, an immediate asthmatic response such as bronchial constriction and edematous formation, in which histamine or the like takes principal part, and a late asthmatic response such as airway constriction due to cell infiltration, mucus secretion or mucosal hypertrophy, in which a leukotriene or the like takes part are considered to be important for the development of morbid conditions. In allergic rhinitis, there is similarly a move toward taking each morbid condition as a biphasic response that histamine takes a profound part in an immediate response such as sternutation or nasal oversecretion and leukotriene takes an important part in a late response such as a rhinostenostic symptom due to edema of the nasal mucosa. A compound having antagonism against both a histamine H 1 receptor and an LTD 4 receptor and less tendency of brain penetration is therefore considered to prevent or cure a variety of allergic diseases, especially a series of symptoms of asthma or rhinitis, which ranges from an immediate response to a late response, and to become an effective pharmaceutical of reduced side effects. It is however the current circumstances that no compound has been found with fully satisfactory antagonism against both an LTD 4 receptor and a histamine H 1 receptor. Further, many of LTD 4 antagonists which have been developed so far contain at least one acidic group, so that these LTD 4 antagonists are hydrophilic compounds having high polarity. They are thus unavoidably insufficient in absorption upon inhalative administration or oral administration. This is believed to have led to the increased doses of these pharmaceuticals and hence, to the development of side effects. Therefore, an object of the present invention is to provide a compound making combined use of both antileukotrienic action and antihistaminic action, having low tendency of brain penetration and containing no acidic group in its molecule; and also a medicine comprising this compound as an effective ingredient. Disclosure of the Invention With the foregoing current circumstances in view, the present inventors have conducted an extensive investigation. As a result, it has been found that novel diamine derivatives represented by the following formula (1) and salts thereof meet the above-described requirements, leading to the completion of the present invention. Specifically, the present invention provides a diamine derivative represented by the following formula (1) or a salt thereof: wherein R 1 represents a hydrogen atom, a hydroxyl group, an aralkyloxy group or a halogen atom; R 2 represents a hydrogen atom or a lower alkyl group; A represents -C(R 3 )=CH-, R 3 being a hydrogen atom or a hydroxyl group, -CH=N-, -N(R 4 )-,R 4 being a lower alkyl group or an alkoxyalkyl group, -O-, or -S-; B represents a single bond, -C(R 5 )(R 6 )-(CH 2 ) k -, R 5 and R 6 being the same or different and individually representing a hydrogen atom or a lower alkyl group, and k being a value of from 0 to 2, -S(O) q CH(R 7 ), q being a value of from 0 to 2, and R 7 being a hydrogen atom or a hydroxyl group, or -CH=CH-; E represents a single bond or -(CH 2 ) 3 -; W and Y may be the same or different and individually represent -CH 2 - or -CO-; Z represents an oxygen atom or a sulfur atom; and ℓ is a value of 0 or 1, m is a value of 2 or 3, and n is a value of from 1 to 4; with the proviso that E is -(CH 2 ) 3 - when B is a single bond and E is a single bond when B is a group other than a single bond. Further, the present invention also provides a medicine comprising as an effective ingredient a diamine derivative represented by the formula (1) or a salt thereof. In addition, the present invention also provides a medicinal composition comprising a diamine derivative represented by the formula (1) or a salt thereof and a pharmaceutically acceptable carrier. Furthermore, the present invention also provides use of a diamine derivative represented by the formula (1) or a salt thereof as a medicine. Moreover, the present invention also provides a method for treating an allergic disease, which comprises administering an effective amount of a diamine derivative represented by the formula (1) or a salt thereof. Best Modes for Carrying Out the Invention In the formula (1), examples of the halogen atom represented by R 1 include fluorine, chlorine, bromine and iodine atoms. Examples of the aralkyloxy group include phenylalkyloxy groups, preferably phenyl-C 1 -C 6 alkyloxy groups, notably a benzyloxy group. As R 1 , a hydrogen atom or a hydroxyl group is preferred. Illustrative of the lower alkyl groups represented by R 2 , R 4 , R 5 and R 6 are linear or branched alkyl groups having 1-6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl and n-hexyl, with methyl being particularly preferred. Illustrative of the alkoxyalkyl group represented by R 4 are C 1-6 alkyl groups substituted by C 1-6 alkoxy groups, for example, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, propoxyethyl, propoxypropyl and propoxybutyl, with ethoxyethyl being particularly preferred. In the formula (1), examples of include the following groups: Further, examples of in the formula (1) include the following groups: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , Z, ℓ, k and q have the same meanings as defined above. No particular limitation is imposed on the salt of the diamine derivative (1) of the present invention, insofar as it is a pharmacologically acceptable salt. Illustrative are mineral acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, sulfate and phosphate; and organic acid addition salts such as the benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, oxalate, maleate, fumarate, tartrate and citrate. Further, the compound of the present invention may also exist in the form of solvates, which are typified by the hydrate, or a keto-enol tautomer. Such solvates and isomer are also included in the present invention. The compound (1) of the present invention can be prepared, for example, in accordance with the following reaction process. wherein A, B, E, R 1 , R 2 , W, Y, Z, ℓ, m and n have the same meanings as defined above, and X represents a chlorine atom, bromine atom or iodine atom. Described specifically, a compound (1) of the present invention in which Y is -CH 2 - can be prepared by reacting a diamine compound (2) with a haloalkylated phenol compound (3) as shown by the process A or by reacting a haloalkylated diamine compound (4) with a phenol compound (5) as shown by the process B. A compound (1) of the present invention in which Y is -CO- can be prepared by reacting a haloacylated diamine compound (4) with a phenol compound (5) as shown by the process B. The above reactions can each be practiced by conducting heating for 1 to 24 hours (preferably at 100 to 200°C) under an inert gas stream in a solventless manner or in an aprotic solvent such as acetone, 2-butanone, dimethylformamide (DMF), dimethylsulfoxide (DMSO) or hexamethylphosphoroamide (HMPA). Upon practice, an inorganic base such as potassium carbonate and an inorganic salt such as potassium iodide may be added. Further, a compound (1) of the present invention in which R 1 is a hydroxyl group can be obtained by subjecting a compound (1) of the present invention, in which R 1 is an aralkyloxy group, to a catalytic hydrogenating reaction in the presence of a catalyst such as palladium on charcoal or in a manner known per se in the art. A description will next be made about synthesis processes of the compounds (2) to (5) useful in the above reactions. The diamine compound (2) for use in the process A can be prepared by a known process, for example, the process disclosed in Pesson, Marcel et al.: Eur. J. Med. Chem.-Chim. Ther., 10 (6), 567-572, 1975; Imura, Ryuichi et al.: J. Heterocycl. Chem., 24 , 31-37, 1987; Meyer, Walter E. et al.: J. Med. Chem., 32 (3), 593-597, 1989; or the like, or in accordance with the reaction scheme shown below. wherein A, R 1 , W, ℓ and m have the same meanings as defined above, Bn represents a benzyl group, and X represents a chlorine atom, bromine atom or iodine atom. Described specifically, a compound (2) in which W is -CH 2 - and m is 2 can be obtained, as shown by the process C, by reacting a halomethyl derivative (6) and N-formylpiperazine in the presence of a base such as pyridine or triethylamine in a polar solvent such as methanol or ethanol at 0°C to reflux temperature (preferably room temperature) for 1 to 7 days to obtain a compound (7) and then reacting and deformylating the compound (7) in a polar solvent such as methanol or ethanol in the presence of an acid, such as concentrated sulfuric acid, added therein at 0°C to reflux temperature (preferably reflux temperature) for 1 to 4 days. A compound (2) in which W is -CH 2 - and m is 3 can be obtained, as shown by the process D, by reacting a halomethyl derivative (6) and homopiperazine in the presence of a base such as triethylamine in a polar solvent such as methanol or ethanol at 0°C to reflux temperature (preferably room temperature) for 1 to 7 days. Further, a compound (2) in which W is -CO- can be obtained, as shown by the process E, by chlorinating a carboxylic acid (8) with thionyl chloride or the like, reacting the chlorinated product with N-benzylpiperazine or N-benzylhomopiperazine to obtain a compound (9), reducingly debenzylating the compound (9), for example, with a palladium-charcoal catalyst or the like under a hydrogen gas stream, and then converting the resulting hydrochloride of the compound (2) into a free base. The haloalkylated phenol compound (3) useful in the process A can be obtained, as shown below, by reacting the phenol compound (10) and a dihalogenide of a linear alkane in an aprotic solvent such as acetone, 2-butanone, DMF, DMSO or HMPA at 0°C to reflux temperature (preferably reflux temperature) for 1 to 24 hours. wherein B, E, R 2 and n have the same meanings as defined above, and X and X' may be the same or different and individually represent a chlorine atom, bromine atom or iodine atom. Among diamine compounds (4) useful in the process B, each compound (4a) in which Y is -CH 2 - can be obtained, as shown below, by reacting a compound (2) and a dihalogenide of a linear alkane in an aprotic solvent such as acetone, 2-butanone, DMF, DMSO or HMPA at 0°C to reflux temperature (preferably reflux temperature) for 1 to 24 hours. wherein A, R 1 , W, ℓ, m and n have the same meanings as defined above, and X and X' may be the same or different and individually represent a chlorine atom, bromine atom or iodine atom. Among the diamine compounds (4) useful in the process B, each compound (4b) in which Y is -CO- can be obtained by haloacylating a compound (2) by a method known per se in the art as shown below. wherein A, R 1 , W, ℓ, m and n have the same meanings as defined above, and X and X' may be the same or different and individually represent a chlorine atom, bromine atom or iodine atom. Incidentally, as the compound (5), compound (6), compound (8) and compound (10), either conventionally known compounds or those prepared by conventionally known processes, for example, by the processes disclosed in Musser, John H. et al.: J. Med. Chem., 33 (1), 240-245, 1990; Iemura, Ryuichi et al.: J. Heterocyclic Chem., 24 (1), 31-37, 1987; Jaromin Gunter E. et al.: Chem. Ber. 120 , 649-651, 1987; White, James D. et al.: J. O. C. 58 , 3466-3468, 1993; etc. can be used. The compound (1) of the present invention can be obtained by treating the reaction mixture by a method known per se in the art subsequent to the reaction by the process A or B. If necessary, it can be purified using a conventional purification method such as recrystallization or column chromatography. By a method known per se in the art, it can be converted into a desired salt as needed. As will be demonstrated subsequently in Examples, the invention compound (1) or salt thereof available as described above has excellent antileukotrienic action and antihistaminic action in combination, has lower tendency of penetration to the center than terfenadine, and is useful as a medicine for asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, urticaria and psoriasis. The medicine according to the present invention comprises the above-described compound (1) or a salt or solvate thereof as an effective ingredient. It is however preferred to use it as a medicinal composition which comprises the effective ingredient and a pharmaceutically acceptable carrier. Its administration forms as such medicinal compositions include, for example, oral administration forms such as tablets, capsules, granules, powders and syrups; and parenteral administration forms such as intravenous injections, intramuscular injections, suppositories, inhalative agents, percutaneous absorption agents, eye drops and nasal drops. Upon production of medicinal preparations in such various administration forms, the effective ingredient can be used either singly or by suitably combining the same with one or more pharmaceutically acceptable carriers such as excipients, binders, extenders, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, corrigents, perfumes, coating materials, diluents and the like. The dosage of the medicine according to the present invention varies depending on the age, body weight, conditions, administration form, administration frequency and the like. In general, however, it is preferred to orally or parenterally administer to an adult the compound (1) or its salt or solvate in an amount of about 1 to 1,000 mg per day at once or in several portions. Examples The present invention will next be described in further detail by the following Examples. It should however be borne in mind that the present invention is by no means limited to these Examples. Preparation Example 1 Synthesis of 1-formyl-4-(2-quinolylmethyl)piperazine After a mixture consisting of 2-chloromethylquinoline hydrochloride (85.64 g, 400 mmol), triethylamine (80.95 g, 800 mmol), N-formylpiperazine (45.66 g, 400 mmol) and ethanol (900 mℓ) was stirred at room temperature for 7 days, the solvent was distilled off under reduced pressure. The resultant residue was dissolved in water, washed with ethyl ether, and then extracted with chloroform. The extract was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, whereby 86.00 g the title compound were obtained as a pale yellow oil (yield: 82.9%). 1 H-NMR(CDCl 3 )δ(ppm): 8.16(1H,d,J=8.3Hz), 8.09(1H,d,J=8.3Hz), 8.06(1H,s), 7.88-7.45(4H,m), 3.88(2H,s), 3.66-3.50(2H,m), 3.48-3.32(2H,m), 2.64-2.45(4H,m). IR(film)cm -1 : 2817, 1665, 1443, 1140, 1018, 1005, 838, 827, 786, 758. Preparation Example 2 Synthesis of 1-(2-quinolylmethyl)piperazine 1-Formyl-4-(2-quinolylmethyl)piperazine (86.00 g, 332 mmol) was dissolved in ethanol (800 mℓ), followed by the addition of concentrated sulfuric acid (49.04 g, 500 mmol). After the resulting mixture was heated under reflux and stirring for 4 days, the solvent was distilled off under reduced pressure. The thus-obtained residue was dissolved in water. After the resulting solution was washed twice with chloroform, the solution was rendered basic with a 10N aqueous solution of sodium hydroxide, followed by extraction with chloroform. The extract was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, whereby 73.65 g of the title compound were obtained as a pale amber oil (yield: 97.6%). 1 H-NMR(CDCl 3 )δ(ppm): 8.13(1H,d,J=8.8Hz), 8.08(1H,d,J=9.3Hz), 7.86-7.56(3H,m), 7.51(1H,t,J=6.8Hz), 3.82(2H,s), 3.00-2.84(4H,m), 2.65-2.44(4H,m). IR(film)cm -1 : 3287, 2939, 2814, 1600, 1504, 1425, 1142, 1131, 1119, 835, 785, 754. Preparation Example 3 Synthesis of 1-(2-quinolylmethyl)homopiperazine After a mixture consisting of 2-chloromethylquinoline hydrochloride (63.16 g, 295 mmol), triethylamine (29.85 g, 295 mmol), homopiperazine (50.08 g, 591 mmol) and ethanol (600 mℓ) was stirred at room temperature for 2 days, the solvent was distilled off under reduced pressure. Water was added to the residue. After the resulting mixture was washed three times with ethyl ether, sodium chloride was added to the water layer, followed by extraction four times with chloroform-methanol (2:1). The extract was washed with an aqueous solution of sodium chloride and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, whereby 28.00 g of the title compound were obtained as a yellow oil (yield: 39.3%). 1 H-NMR(CDCl 3 )δ(ppm): 8.15(1H,d,J=8.8Hz), 8.06(1H,d,J=8.3Hz), 7.79(2H,d,J=7.8Hz), 7.68(2H,d,J=8.8Hz), 7.52(1H,t,J=6.8Hz), 4.03(2H,s), 3.30-3.06(4H,m), 3.00-2.70(4H,m), 2.06-1.90(2H,m). IR(film)cm -1 : 3100-2300, 1618, 1600, 1504, 1461, 1426, 1356, 1310, 1142, 1114, 1085, 1054, 834, 753. Further, the ethyl ether washing was washed with water and then dried over anhydrous magnesium sulfate. The solvent was thereafter distilled off, whereby 18.15 g of 1,4-bis(2-quinolylmethyl)homopiperazine were obtained as a yellow oil (yield: 32.2%). A portion of the oil was crystallized from a mixed solvent of ethyl ether and n-hexane, whereby pale yellow prisms were obtained. m.p.: 65-67°C 1 H-NMR(CDCl 3 )δ(ppm): 8.13(2H,d,J=8.8Hz), 8.06(2H,d,J=8.8Hz), 7.84-7.62(6H,m), 7.50(2H,td,J=8.3,1.5Hz), 4.00(4H,s), 2.92-2.73(8H,m), 2.00-1.78(2H,m). IR(film)cm -1 : 3059, 2935, 2815, 1618, 1600, 1563, 1504, 1458, 1425, 1355, 1335, 1112, 833, 785, 757. Preparation Examples 4-11 By similar processes as in Examples 1-3 or known processes, the compounds shown in Table 1 were obtained. Prep. Ex. Compound Name Color, state of matter 4 1-(2-Quinazolinylmethyl)piperazine Amber oil 5 1-(N-Methylbenzoimidazol-2-yl-methyl)piperazine Amber oil 6 1-(N-Methylbenzoimidazol-2-yl-methyl)homopiperazine Amber oil 7 1-(N-Ethoxyethylbenzoimidazol-2-yl-methyl)piperazine Amber oil 8 1-(N-Ethoxyethylbenzoimidazol-2-yl-methyl)homopiperazine Amber oil 9 1-(1-Oxo-2-quinolylmethyl)piperazine Amber oil 10 1-(8-Benzyloxy-2-quinolylmethyl)piperazine Colorless oil 11 1-(4-Benzyloxy-2-quinolylmethyl)piperazine Amber oil Preparation Example 12 Synthesis of 7-(3-chloropropoxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one After a mixture consisting of 7-hydroxy-3,4-dihydro-2H-1,4-benzothiazin-3-one (1.812 g, 10 mmol), 1-bromo-3-chloropropane (2.362 g, 15 mmol), potassium carbonate (4.146 g, 30 mmol) and acetone (40 mmol) was heated under reflux and stirring for 24 hours, insoluble matter was filtered off, and the solvent was distilled off under reduced pressure. The residue was subjected to chromatography on a silica gel column (developer: chloroform) to purify the same, and was then recrystallized from acetone. The title compound (1.300 g) was obtained as yellow leaflets (yield: 50.4%). m.p.: 150-152°C 1 H-NMR(CDCl 3 )δ(ppm): 8.80(1H,br.s), 6.87(1H,d,J=2.4Hz), 6.82(1H,d,J=8.8Hz), 6.73(1H,dd,J=8.3,2.4Hz), 4.08(2H,t,J=5.8Hz), 3.74(2H,t,J=5.8Hz), 3.42(2H,s), 2.32-2.14(2H,m). IR(KBr)cm -1 : 3262, 1671, 1635, 1502, 1468, 1387, 1243, 1233, 1033. Preparation Examples 13-56 From known compounds or compounds available by known processes, the compounds shown in Tables 2 and 3 were obtained in a similar manner as in Preparation Example 12. Prep. EX. Compound Name Melting point(°C) 13 6-(3-Chloropropoxy)-2,3,4,5-tetrahydro-1H-1-benzoazepin-2-one 110-112 14 7-(3-Chloropropoxy)-2,3,4,5-tetrahydro-1H-1-benzoazepin-2-one 121-123 15 7-(3-Chloropropoxy)-2,3,4,5-tetrahydro-1H-2-benzoazepin-1-one 132-133 16 7-(2-Chloroethoxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one 179-181 17 7-(4-Chlorobutoxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one 137-139 18 7-(5-Chloropentyloxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one 121-123 19 5-(3-Chloropropoxy)-8-methyl-1,2-dihydroquinolin-2-one 162-165 20 6-(3-Chloropropoxy)-1,2-dihydroquinolin-2-one 196-198 21 7-(2-Chloroethoxy)-1,2-dihydroquinolin-2-one 182-184 22 7-(3-Chloroethoxy)-1,2-dihydroquinolin-2-one 124-126 23 5-(2-Chloroethoxy)-8-methyl-1,2,3,4-tetrahydroquinolin-2-one 161-162 24 5-(3-Chloropropoxy)-8-methyl-1,2,3,4-tetrahydroquinolin-2-one 146-147 25 5-(4-Chlorobutoxy)-8-methyl-1,2,3,4-tetrahydroquinolin-2-one 120-121 26 5-(5-Chloropentyloxy)-8-methyl-1,2,3,4-tetrahydroquinolin-2-one 115-116 27 6-(2-Chloroethoxy)-1,2,3,4-tetrahydroquinolin-2-one 150-152 28 6-(3-Chloropropoxy)-1,2,3,4-tetrahydroquinolin-2-one 133-135 29 6-(4-Chlorobutoxy)-1,2,3,4-tetrahydroquinolin-2-one 146-147 30 6-(5-Chloropentyloxy)-1,2,3,4-tetrahydroquinolin-2-one 102-104 31 7-(2-Chloroethoxy)-1,2,3,4-tetrahydroquinolin-2-one 137-138 32 7-(3-Chloropropoxy)-1,2,3,4-tetrahydroquinolin-2-one 126-127 33 7-(4-Chlorobutoxy)-1,2,3,4-tetrahydroquinolin-2-one 104-105 34 7-(5-Chloropentyloxy)-1,2,3,4-tetrahydroquinolin-2-one 130-131 Prep. Ex. Compound Name Melting point(°C) 35 7-(3-Chloropropoxy)-4,4-tetrahydroquinolin-2-one 147-148 36 8-(3-Chloropropoxy)-1,2,3,4-tetrahydroquinolin-2-one 151-153 37 8-(4-Chloropropoxy)-1,2,3,4-tetrahydroquinolin-2-one 129-131 38 4-(3-Chloropropoxy)-2,3-dihydro-1H-indol-2-one 142-144 39 4-(2-Chloroethoxy)-3,3,7-trimethyl-2,3-dihydro-1H-indol-2-one 153-154 40 4-(3-Chloropropoxy)-3,3,7-trimethyl-2,3-dihydro-1H-indol-2-one 185-187 41 4-(4-Chlorobutoxy)-3,3,7-trimethyl-2,3-dihydro-1H-indol-2-one 161-162 42 4-(5-Chloropentyloxy)-3,3,7-trimethyl-2,3-dihydro-1H-indol-2-one 142-143 43 4-(3-Chloropropoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 149-151 44 5-(2-Chloroethoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 153-155 45 5-(3-Chloropropoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 102 46 5-(4-Chlorobutoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 94 47 5-(5-Chloropentyloxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 94-95 48 6-(2-Chloroethoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 139-140 49 6-(3-Chloropropoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 130-131 50 6-(4-Chlorobutoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 126 51 6-(5-Chloropentyloxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 156-157 52 7-(3-Chloropropoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 170-171 53 7-(4-Chlorobutoxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 158-159 54 7-(5-Chloropentyloxy)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 110-111 55 7-(3-Chloropropoxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one-1-oxide 180-182 (dec.) 56 7-(3-Chloropropoxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one-1,1-dioxide 172-174 Preparation Example 57: Synthesis of 1-(3-chloropropyl)-4-(2-quinolylmethyl)piperazine A mixture consisting of 1-(2-quinolylmethyl)-piperazine (21.75 g, 95.7 mmol), potassium carbonate (19.90 g, 144 mmol), 1-bromo-3-chloropropane (16.57 g, 105 mmol) and acetone (250 mℓ) was heated under reflux and stirring for 20 hours, insoluble matter was removed and the solvent was distilled off. The oil residue was dissolved in chloroform and the resulting solution was then subjected to chromatography on a silica gel column (developer: chloroform/methanol = 100/1), whereby 19.10 g of the title compound were obtained as a yellow oil (yield: 65.7%). 1 H-NMR(CDCl 3 )δ(ppm): 8.12(1H,d,J=8.8Hz), 8.08(1H,d,J=9.8Hz), 7.80(1H,d,J=8.3Hz), 7.70(1H,td,J=5.9,1.5Hz), 7.63(1H,d,J=8.3Hz), 7.51(1H,t,J=6.8Hz), 3.85(2H,s), 3.59(2H,t,J=6.3Hz), 2.72-2.40(10H,m), 2.10-1.80(2H,m). IR(film)cm -1 : 2940, 2812, 1600, 1504, 1458, 1425, 1299, 1160, 1132, 1013, 838, 757. Preparation Example 58 Synthesis of 1-(3-chloropropyl)-4-(2-quinolylmethyl)homopiperazine In a similar manner as in Preparation Example 57, the title compound was obtained as a pale amber oil from 1-(2-quinolymethyl)homopiperazine (yield: 76.1%). 1 H-NMR(CDCl 3 )δ(ppm): 8.12(1H,d,J=8.3Hz), 8.06(1H,d,J=8.8Hz), 7.80(1H,d,J=7.8Hz), 7.75-7.59(1H,m), 7.70(1H,t,J=8.3Hz), 7.50(1H,td,J=8.3,1.0Hz), 3.97(2H,s), 3.61(2H,t,J=6.3Hz), 2.85-2.55(10H,m), 2.00-1.72(4H,m). IR(film)cm -1 : 2938, 2815, 1600, 1504, 1425, 1356, 1115, 832. Preparation Example 59 Synthesis of 1-(1-chloroacetyl)-4-(2-quinolylmethyl)piperazine After a mixture consisting of 1-(2-quinolylmethyl)piperazine (12.40 g, 54.6 mmol), chloroacetyl chloride (6.17 g, 54.6 mmol), triethylamine (5.52 g, 54.6 mmol) and acetone (200 mℓ) was stirred at room temperature for 1 hour, insoluble matter was removed and the solvent was then distilled off. The oil residue was dissolved in chloroform and the resulting solution was then subjected to chromatography on a silica gel column (developer: chloroform), whereby 12.62 g of the title compound were obtained as an amber oil (yield: 76.1%). 1 H-NMR(CDCl 3 )δ(ppm): 8.15(1H,d,J=8.5Hz), 8.08(1H,d,J=8.3Hz), 7.81(1H,d,J=8.3Hz), 7.70(1H,td,J=6.8Hz,1.5Hz), 7.61(1H,d,J=8.6Hz), 7.53(1H,t,J=8.0Hz), 4.06(2H,s), 3.88(2H,s), 3.68(2H,t,J=5.1Hz), 3.56(2H,t,J=5.1Hz), 2.60(4H,qw,J=4.8Hz). IR(film)cm -1 : 2941, 2809, 1712, 1663, 1618, 1600, 1504, 1461, 1426, 1366, 1329, 1302, 1279, 1252, 1223, 1142, 1002, 835, 786, 757. Preparation Example 60 Synthesis of 1-benzyl-4-(2-quinolylcarbonyl) piperazine hydrochloride Thionyl chloride (6 mℓ) was added to a suspension of quinaldinic acid (3.463 g, 20 mmol) in chloroform (40 mℓ). After the resulting mixture was heated under reflux and stirring for 6 hours, the solvent was distilled off. The residue was dissolved in acetone (50 mℓ), followed by the addition of a solution of N-benzylpiperazine (10.576 g, 60 mmol) in acetone (50 mℓ). The thus-obtained mixture was stirred for 1 hour. A deposited precipitate was removed, and the solvent was distilled off. The residue was dissolved in ethyl ether. The resulting solution was washed with an aqueous solution of sodium chloride, and then dried over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was dissolved in methanol, followed by the addition of concentrated hydrochloric acid (5 mℓ) for acidification. The solvent was distilled off and the thus-obtained residue was crystallized from a mixed solvent of ethanol and methanol, whereby 7.166 g of the title compound were obtained as white powder (yield: 97.5%). m.p.: 235-237°C (dec.) 1 H-NMR(DMSO-d 6 )δ(ppm): 11.68(1H,br.s), 8.55(1H,d,J=8.3Hz), 8.06(1H,d,J=9.8Hz), 7.92-7.55(6H,m), 7.52-7.37(3H,m), 4.65(1H,d,J=12Hz), 4.37(2H,s), 4.18(1H,d,J=12Hz), 3.85-3.00(6H,m). IR(KBr)cm -1 : 2800-2200, 1644, 1474, 1416, 1290, 1100, 1040, 953, 838, 778, 770, 759, 704. Preparation Example 61 Synthesis of 1-(2-quinolylcarbonyl)piperazine hydrochloride After a mixture consisting of 1-benzyl-4-(2-quinolylcarbonyl)piperazine hydrochloride (18.81 g, 51.1 mmol), 10% palladium-charcoal catalyst (3.00 g) and water (150 mℓ) was stirred for 3 hours at a bath temperature of 70°C under a hydrogen gas stream, the catalyst was removed and the solvent was then distilled off. The residue was crystallized from ethanol, whereby 11.03 g of the title compound were obtained as colorless prisms (yield: 77.7%). m.p.: 236-237°C (dec.) 1 H-NMR(DMSO-d 6 )δ(ppm): 9.48(1H,br.s), 8.55(1H,d,J=8.8Hz), 8.07(2H,d,J=8.3Hz), 7.91-7.64(3H,m), 4.02-3.70(4H,br), 3.30-3.02(4H,br). IR(KBr)cm -1 : 2938, 2744, 2716, 2711, 2475, 1647, 1593, 1472, 1436, 1421, 1289, 843, 789, 767. Preparation Example 62 Synthesis of 1-(2-quinolylcarbonyl)piperazine 1-(2-Quinolylcarbonyl)piperazine hydrochloride (6.18 g, 22.2 mmol) was dissolved in water. The thus-obtained solution was rendered basic with a concentrated aqueous solution of sodium hydroxide. The resulting mixture was extracted with chloroform, and the extract was washed with an aqueous solution of sodium chloride and then dried over anhydrous magnesium sulfate. The solvent was distilled off, whereby 4.236 g of the title compound were obtained as a colorless oil (yield: 79.1%). 1 H-NMR(CDCl 3 )δ(ppm): 8.27(1H,d,J=8.3Hz), 8.11(1H,d,J=8.3Hz), 7.91-7.57(4H,m), 3.87(2H,t,J=5.4Hz), 3.66(2H,t,J=5.4Hz), 3.04(2H,t,J=5.4Hz). IR(KBr)cm -1 : 3301, 2947, 2917, 1629, 1597, 1561, 1479, 1441, 1424, 1288, 1173, 1140, 1118, 1024, 845, 819, 776, 764, 621. Example 1 Synthesis of 3,3-dimethyl-5-{2-[4-(2-quinolylmethyl)-1-piperazinyl]ethoxy}-2,3-dihydro-1H-indol-2-one 5-(2-Chloroethoxy)-3,3-dimethyl-2,3-dihydroindol-2-one (182 mg, 3.0 mmol) and N-(2-quinolylmethyl)-piperazine (690 mg, 3.0 mmol) were mixed, followed by stirring at 150°C for 3 hours under an argon gas stream. The resulting mixture was allowed to cool down, and was then dissolved in chloroform. The thus-obtained solution was washed with water and then dried over anhydrous sodium sulfate. After the solution was concentrated under reduced pressure, the residue was purified by chromatography on a silica gel column while using chloroform-methanol (10:1) as an eluent. Fractions containing the target compound were collected and then concentrated under reduced pressure. The concentrate was crystallized from n-hexane and was then recrystallized from ethyl acetate-ethyl ether, whereby 240 mg of the title compound were obtained as pale yellow powder (yield: 73%). m.p.: 187-189°C (dec.) 1 H-NMR(CDCl 3 )δ(ppm): 8.57(1H,br.s), 8.12(1H,d,J=8.5Hz), 8.07(1H,d,J=8.8Hz), 7.80(1H,d,J=8.3Hz), 7.69(1H,dt,J=8.6,1.5Hz), 7.63(1H,d,J=8.3Hz), 7.51(1H,dt,J=8.1,1.2Hz), 6.80(1H,d,J=8.4Hz), 6.80(1H,d,J=2.4Hz), 6.71(1H,dd,J=8.4,2.4Hz), 4.08(2H,t,J=5.9Hz), 3.86(2H,s), 2.82(2H,t,J=5.9Hz), 2.65(8H,br.s), 1.37(6H,s). IR(KBr)cm -1 : 3424, 3171, 3088, 3045, 2965, 2927, 2870, 2810, 1709, 1603, 1566, 1500, 1482, 1456, 1427, 1393, 1331, 1311, 1278, 1206, 1158, 1135, 1091, 1076, 1050, 1014, 973, 958, 870, 854, 840, 824, 761, 737, 653, 579, 482, 459. Example 2 Synthesis of 3,3,7-trimethyl-4-{3-[4-(N-ethoxyethylbenzoimidazol-2-ylmethyl)-1-piperazinyl]propoxy)-2,3-dihydro-1H-indol-2-one dimaleate A mixture consisting of 3,3,7-trimethyl-4-(3-chloropropoxy)-2,3-dihydro-1H-indol-2-one (268 mg, 1.00 mmol) and 1-(N-ethoxyethylbenzoimidazol-2-ylmethyl)-piperazine (1.15 g, 4.00 mmol) was stirred for 4 hours at a bath temperature of 150°C under an argon gas stream. The reaction mixture was dissolved in chloroform. The thus-obtained solution was washed with water, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by subjecting it to chromatography on a silica gel column (developer: chloroform/methanol(saturated with ammonia) = 20/1). Fractions containing the target compound were collected and then concentrated under reduced pressure, whereby 458 mg of the free base of the title compound were obtained as an amber oil (88.1%). The oil was dissolved in methanol, to which anhydrous maleic acid (205 mg, 1.77 mmol) was added to convert the free base into its dimaleate. The dimaleate was then recrystallized from a mixed solvent of methanol and acetone, whereby 512 mg of the title compound were obtained as white powder (yield: 77.3%). m.p.: 163-165°C (dec.) 1 H-NMR(CDCl 3 )δ(ppm): 10.30(1H,s), 7.61(1H,m), 7.58(1H,m), 7.27(1H,m), 7.21(1H,m), 6.91(1H,d,J=8.5Hz), 6.50(1H,d,J=8.5Hz), 6.14(4H,s), 4.52(1H,br.t,J=5.1Hz), 4.08-3.96(4H,m), 3.72(2H,br.t,J=5.1Hz), 3.39(2H,q,J=7.1Hz), 3.50-2.80(8H,br), 3.22(2H,br), 2.14(3H,s), 1.31(6H,s), 1.04(3H,t,J=7.1Hz). IR(KBr)cm -1 : 2977, 2869, 1705, 1614, 1582, 1509, 1485, 1465, 1385, 1361, 1091, 866. Example 3 Synthesis of 7-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-2,3,4,5-tetrahydro-1H-1-benzoazepin-2-one A mixture consisting of 7-(3-chloropropoxy)-2,3,4,5-tetrahydro-1H-benzoazepin-2-one (0.304 g, 1.2 mmol) and 1-(2-quinolylmethyl)piperazine (1.091 g, 4.8 mmol) was stirred for 4 hours at a bath temperature of 150°C under an argon gas stream. The reaction mixture was dissolved in chloroform. The thus-obtained solution was rendered basic with a dilute aqueous solution of sodium hydroxide, washed with water, and then dried over magnesium sulfate. After the resulting solution was purified by subjecting it to chromatography on a silica gel column (developer: chloroform/methanol = 40/1), recrystallization was conducted from acetone. The title compound (0.270 g) was obtained as yellow prisms (yield: 50.6%). m.p.: 131-133°C 1 H-NMR(CDCl 3 )δ(ppm): 8.10(2H,t,J=8.8Hz), 7.85-7.44(1H,m),7.32(1H,br.s), 6.92-6.66(3H,m), 4.00(2H,t,J=6.3Hz), 3.86(2H,s), 2.75(2H,t,J=7.3Hz), 2.68-2.40(10H,m), 2.40-2.07(4H,m), 2.05-1.88(2H,m). IR(KBr)cm -1 : 1672, 1499, 1424, 1385, 1255, 1238, 1170, 1163, 1155, 1057, 835, 807, 749. Example 4 Synthesis of 7-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-2,3,4,5-tetrahydro-1H-2-benzoazepin-1-one A mixture consisting of 7-(chloropropoxy)-2,3,4,5-tetrahydro-1H-2-benzoazepin-1-one (0.507 g, 2 mmol) and 1-(2-quinolylmethyl)piperazine (1.81 g, 8 mmol) was stirred for 4 hours at a bath temperature of 150°C under an argon gas stream. After the reaction mixture was allowed to cool down, chloroform was added to the reaction mixture to dissolve the same. The resulting solution was rendered basic with a dilute aqueous solution of sodium hydroxide. The thus-obtained solution was washed with water and then dried over anhydrous magnesium sulfate. After the resulting solution was purified by subjecting it to chromatography on a silica gel column (developer: chloroform/methanol = 40/1), recrystallization was conducted from acetone. The title compound (0.613 g) was obtained as yellow leaflets (yield: 68.9%). m.p.: 161-162°C 1 H-NMR(CDCl 3 )δ(ppm): 8.11(2H,t,J=8.8Hz), 7.78(1H,td,J=9.8,1.5Hz), 7.75-7.58(4H,m), 7.51(1H,td,J=6.9,1.0Hz), 6.84(1H,dd,J=8.3,2.4Hz), 6.71(1H,d,J=2.4Hz), 6.52-6.34(1H,br), 4.05(2H,t,J=6.4Hz), 3.86(2H,s), 3.12(2H,t,J=6.4Hz), 2.83(2H,t,J=6.8Hz), 2.72-2.40(10H,m), 2.09-1.88(4H,m). IR(KBr)cm -1 : 2940, 2805, 1652, 1601, 1246. Example 5 Synthesis of 7-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one-1-oxide A mixture consisting of 7-(3-chloropropoxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one-1-oxide (2.02 g, 7.38 mmol), N-(2-quinolylmethyl)piperazine (2.52 g, 11.07 mmol), potassium carbonate (2.04 g, 14.76 mmol), potassium iodide (2.45 g, 14.76 mmol) and DMF (50 mℓ) was stirred at 80°C for 4 hours. The solvent was distilled off from the reaction mixture under reduced pressure, followed by the addition of water. The resulting mixture was extracted with chloroform-methanol (10:1). The extract was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by chromatography on a silica gel column while using chloroform-ammonia-saturated methanol (10:1) as an eluent. Fractions containing the target compound were collected and then concentrated under reduced pressure, whereby 1.23 g of the title compound was obtained as a yellow oil (4.49 mmol, 60.9%). 1 H-NMR(CDCl 3 )δ(ppm): 8.89(1H,br.s), 8.13(1H,d,J=8.6Hz), 8.07(1H,d,J=8.6Hz), 7.81(1H,d,J=8.1Hz), 7.70(1H,ddd,J=8.6,7.1,1.5Hz), 7.63(1H,d,J=8.6Hz), 7.52(1H,ddd,J=8.1,6.8,1.2Hz), 7.25(1H,d,J=2.7Hz), 7.06(1H,dd,J=8.8,2.7Hz), 6.97(1H,d,J=8.8Hz), 4.12(1H,d,J=5.4Hz), 4.04(2H,t,J=6.4Hz), 3.87(2H,s), 3.66(1H,d,J=5.4Hz), 2.70-2.42(10H,cm), 2.00(2H,br). IR(KBr)cm -1 : 2940, 2816, 1686, 1500, 1228, 1039. Examples 6-49 In a similar manner as in Examples 1-5, the compounds shown in Tables 4-6 were obtained. Some of the compounds were converted into salts with maleic acid by a method known per se in the art. Ex. Compound Name Melting point(°C) 6 7-{3-[4-(2-Quinazolinylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 155-157 7 3,3,7-Trimethyl-4-{4-[4-(2-quinolylmethyl)-1-piperazinyl]butoxy}-2,3-dihydro-1H-indol-2-one 148-149 8 7-{5-[4-(2-Quinolylmethyl)-1-piperazinyl]pentyloxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 150-151 9 3,3,7-Trimethyl-4-{5-[4-(2-quinolylmethyl)-1-piperazinyl]pentyloxy}-2,3-dihydro-1H-indol-2-one 141-146 10 7-{4-[4-(2-Quinolylmethyl)-1-piperazinyl]butoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 152-153 11 4-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 159-160 12 8-Methyl-5-{2-[4-(2-quinolylmethyl)-1-piperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 149-150 13 8-Methyl-5-{4-[4-(2-quinolylmethyl)-1-piperazinyl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one 115-117 14 8-Methyl-5-{5-[4-(2-quinolylmethyl)-1-piperazinyl]pentyloxy}-1,2,3,4-tetrahydroquinolin-2-one 147-148 15 6-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-2,3,4,5-tetrahydro-1H-1-benzoazepin-2-one 130-131 16 3,3-Dimethyl-5-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 137-138 17 3,3-Dimethyl-5-{4-[4-(2-quinolylmethyl)-1-piperazinyl]butoxy}-2,3-dihydro-1H-indol-2-one 119-120 18 3,3-Dimethyl-5-{5-[4-(2-quinolylmethyl)-1-piperazinyl]pentyloxy}-2,3-dihydro-1H-indol-2-one 109-110 19 6-{2-[4-(2-Quinolylmethyl)-1-piperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 154-156 20 6-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 176-178 21 6-{4-[4-(2-Quinolylmethyl)-1-piperazinyl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one 150-152 Ex. Compound Name Melting point(°C) 22 6-{5-[4-(2-Quinolylmethyl)-1-piperazinyl]pentyloxy}-1,2,3,4-tetrahydroquinolin-2-one 140-142 23 4,4-Dimethyl-7-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 190-192 (dec.) 24 3,3,7-Trimethyl-4-{3-[4-(2-quinazolinylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 162-164 25 8-Methyl-5-{3-[4-(2-quinazolinylmethyl)-1-piperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 145-147 26 3,3,7-Trimethyl-4-{3-[4-(N-methylbenzoimidazol-2-ylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 150-153 (dec.) 27 7-{3-[4-(N-Methylbenzoimidazol-2-ylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 176-179 (dec.) 28 7-{3-[4-(N-Ethoxyethylbenzoimidazol2-ylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 178-181 (dec.) 29 3,3-Dimethyl-7-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 111-112 30 3,3-Dimethyl-7-{4-[4-(2-quinolylmethyl)-1-piperazinyl]butoxy}-2,3-dihydro-1H-indol-2-one 133-134 31 6-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-1,2-dihydroquinolin-2-one 169-171 32 7-{2-[4-(2-Quinolylmethyl)-1-piperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 148-150 33 7-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 199-200 (dec.) 34 7-{4-[4-(2-Quinolylmethyl)-1-piperazinyl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one 145-147 35 7-{5-[4-(2-Quinolylmethyl)-1-piperazinyl]pentyloxy)-1,2,3,4-tetrahydroquinolin-2-one 116-117 36 7-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-1,2-dihydroquinolin-2-one 155-157 Ex. Compound Name Melting point(°C) 37 3,3,7-Trimethyl-4-{5-[4-(2-quinolylmethyl)-1-piperazinyl]pentyloxy}-2,3-dihydro-1H-indol-2-one 121-122 38 3,3-Dimethyl-6-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 143-144 39 7-{2-[4-(2-Quinolylmethyl)-1-piperazinyl]ethoxy}-1,2-dihydroquinolin-2-one 188-190 (dec.) 40 3,3-Dimethyl-6-{2-[4-(2-quinolylmethyl)-1-piperazinyl]ethoxy}-2,3-dihydro-1H-indol-2-one 161-162 41 3,3-Dimethyl-4-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 162-163 42 3,3-Dimethyl-6-{5-[4-(2-quinolylmethyl)-1-piperazinyl]pentyloxy}-2,3-dihydro-1H-indol-2-one 144-145 43 3,3-Dimethyl-6-{4-[4-(2-quinolylmethyl)-1-piperazinyl]butoxy}-2,3-dihydro-1H-indol-2-one 138-140 44 8-{4-[4-(2-Quinolylmethyl)-1-piperazinyl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one 174-177 (dec.) 45 8-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 172 (dec.) 46 7-{3-[4-(2-Quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one-1,1-dioxide 204-206 (dec.) 47 7-{3-[4-(4-Benzyloxy-2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 151-154 48 7-(3-[4-(8-Benzyloxy-2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one-1,1-dioxide Amorphous 49 7-{3-[4-(1-Oxo-2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one-1,1-dioxide 175-177 (dec.) Example 50 Preparation of 3,3-dimethyl-5-{2-[4-(2-quinolylmethyl)-1-homopiperazinyl]ethoxy}-2,3-dihydro-1H-indol-2-one dimaleate 5-(2-Chloroethoxy)-3,3-dimethyl-2,3-dihydroindol-2-one (214 mg, 0.89 mmol) and N-(2-quinolylmethyl)-homopiperazine (1.07 mg, 4.45 mmol) were mixed, followed by stirring at 150°C for 3 hours under an argon gas stream. The reaction mixture was allowed to cool down, and was then dissolved in chloroform. The resulting solution was washed with water and then dried over anhydrous sodium sulfate. After the solution was concentrated under reduced pressure, the residue was purified by chromatography on a silica gel while using chloroform-methanol (10:1) as an eluent. Fractions containing the target compound were collected and then concentrated under reduced pressure, whereby 127 mg of the free base of the title compound were obtained as an amber oil (32%). The oil was dissolved in methanol, to which anhydrous maleic acid (66 mg, 0.57 mmol) was added to convert the free base into its dimaleate. The dimaleate was crystallized from ethyl ether, whereby 170 mg of the title compound were obtained as pale yellow powder (yield: 28%). m.p.: 145-147°C (dec.) 1 H-NMR(DMSO-d 6 )δ(ppm): 8.40(1H,d,J=8.6Hz), 8.01-7.98(2H,m), 7.78(1H,dt,J=8.3,1.5Hz), 7.68-7.59(2H,m), 6.99(1H,br.s), 6.78-6.77(2H,m), 6.13(4H,s), 4.25(2H,s), 4.21(2H,t,J=5.1Hz), 3.45-3.16(8H,br.s), 3.03(2H,t,J=5.1Hz), 2.06-2.00(2H,m), 1.23(6H,s). IR(KBr)cm -1 : 1717, 1695, 1674, 1577, 1483, 1386, 1363, 1280, 1202, 1088, 1006, 930, 877, 865, 833, 814, 710, 571. Example 51 Synthesis of 7-{3-[4-(N-methylbenzoimidazol-2-ylmethyl)-1-homopiperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one A mixture consisting of 7-(3-chloropropoxy)-3,4-dihydro-2H-1,4-benzothiazin-3-one (303 mg, 1.18 mmol) and 1-(N-methylbenzoimidazol-2-ylmethyl-1-homopiperazine (4.71 mmol) was stirred for 4 hours at a bath temperature of 120°C under an argon gas stream. The reaction mixture was dissolved in chloroform. The resulting solution was washed with water, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was subjected to chromatography on a silica gel column (developer: chloroform/methanol(saturated with ammonia) = 20/1) for purification. Recrystallization was then conducted from a mixed solvent of chloroform and ethyl ether, whereby 507 mg of the title compound were obtained as colorless needles (yield: 92.3%). m.p.: 123-125°C 1 H-NMR(CDCl 3 )δ(ppm): 9.04(1H,s), 7.72(1H,m), 7.37-7.20(3H,m), 6.84(1H,d,J=2.7Hz), 6.80(1H,d,J=8.8Hz), 6.70(1H,dt,J=8.8,2.7Hz), 3.95(2H,t,J=6.4Hz), 3.92(2H,s), 3.89(3H,s), 3.40(2H,s), 2.80-2.58(10H,m), 1.95-1.74(4H,m). IR(KBr)cm -1 : 2940, 1668, 1607, 1498, 1475, 1237, 1120, 1069, 832, 737. Examples 52-89 In a similar manner as in Examples 50 and 51, the compounds shown in Tables 7-9 were obtained. Some of the compounds were converted into salts with maleic acid or oxalic acid by a method known per se in the art. Ex. Compound Name Melting point(°C) 52 7-{5-[4-(2-Quinolylmethyl)-1-homopiperazinyl]pentyloxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 97-99 53 3,3,7-Trimethyl-4-{5-[4-(2-quinolylmethyl)-1-homopiperazinyl]pentyloxy}-2,3-dihydro-1H-indol-2-one 90-91 54 3,3,7-Trimethyl-4-{2-[4-(2-quinolylmethyl)-1-homopiperazinyl]ethoxy}-2,3-dihydro-1H-indol-2-one 153-155 (dec.) a) 55 3,3,7-Trimethyl-4-{4-[4-(2-quinolylethyl)-1-homopiperazinyl]butoxy}-2,3-dihydro-1H-indol-2-one 122-124 (dec.) a) 56 7-{2-[4-(2-Quinolylmethyl)-1-homopiperazinyl]ethoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 126-128 57 7-{4-[4-(2-Quinolylmethyl)-1-homopiperazinyl]ethoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 86-88 58 8-Methyl-5-{5-[4-(2-quinolylmethyl)-1-homopiperazinyl]pentyloxy}-1,2,3,4-tetrahydroquinolin-2-one 143-145 (dec.) a) 59 8-Methyl-5-{4-[4-(2-quinolylmethyl)-1-homopiperazinyl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one 146-148 (dec.) a) 60 8-Methyl-5-{3-[4-(2-quinolylmethyl)-1-homopiperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 154-156 a) 61 8-Methyl-5-{2-[4-(2-quinolylmethyl)-1-homopiperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 156-157 (dec.) a) 62 3,3-Dimethyl-5-{3-[4-(2-quinolylmethyl)-1-homopiperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 139-140 a) 63 6-{2-[4-(2-Quinolylmethyl)-1-homopiperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 139-141 (dec.) a) 64 6-{3-[4-(2-Quinolylmethyl)-1-homopiperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 158-161 (dec.) 65 6-{4-[4-(2-Quinolylmethyl)-1-homopiperazinyl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one 159-161 (dec.) a) 66 6-{5-[4-(2-Quinolylmethyl)-1-homopiperazinyl]pentyloxy}-1,2,3,4-tetrahydroquinolin-2-one 143-145 (dec.) a) Ex. Compound Name Melting point(°C) 67 6-{3-[4-(2-Quinolylmethyl)-1-homopiperazinyl]propoxy}-2,3,4,5-tetrahydro-1H-1-benzoazepin-2-one 129-131 (dec.) a) 68 4,4-Dimethyl-7-{3-[4-(2-quinolylmethyl)-1-homopiperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 157-159 (dec.) a) 69 3,3-Dimethyl-7-{3-[4-(2-quinolylmethyl)-1-homopiperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 133-134 (dec.) a) 70 6-{3-[4-(2-Quinolylmethyl)-1-homopiperazinyl]propoxy}-1,2-dihydroquinolin-2-one 161-163 (dec.) a) 71 7-{3-[4-(2-Quinolylmethyl)-1-homopiperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one 158-160 (dec.) a) 72 7-{4-[4-{2-Quinolylmethyl)-1-homopiperazinyl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one 153-155 (dec.) 73 7-{5-[4-(2-Quinolylmethyl)-1-homopiperazinyl]pentyloxy}-1,2,3,4-tetrahydroquinolin-2-one 143-145 (dec.) a) 74 7-{3-[4-(2-Quinolylmethyl)-1-homopiperazinyl]propoxy}-1,2-dihydroquinolin-2-one 151-153 (dec.) a) 75 6-{2-[4-(N-Methylbenzoimidazol-2-ylmethyl)-1-homopiperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 146-147 (dec.) a) 76 8-Methyl-5-{2-[4-(N-methylbenzoimidazol-2-ylmethyl)-1-homopiperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 163-165 (dec.) a) 77 6-{2-[4-(N-Methylbenzoimidazol-2-ylmethyl)-1-homopiperazinyl]ethoxy}-1,2-dihydroquinolin-2-one 166-169 a) 78 3,3-Dimethyl-6-{3-[4-(2-quinolylmethyl)-1-homopiperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 132-135 (dec.) a) 79 7-{2-[4-(2-Quinolylmethyl)-1-homopiperazinyl]ethoxy}-1,2-dihydroquinolin-2-one 151-153 (dec.) a) 80 7-{2-[4-(N-Methylbenzoimidazol-2-ylmethyl)-1-homopiperazinyl]ethoxy}-1,2-dihydroquinolin-2-one 119-121 (dec.) 81 7-{2-[4-(2-Quinolylmethyl)-1-homopiperazinyl]ethoxy}-1,2,3,4-tetrahydroquinolin-2-one 155-157 (dec.) a) Example 90 Synthesis of 7-{3-[4-(2-quinolylmethyl) piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one After a mixture consisting of 7-hydroxy-3,4-dihydro-2H-1,4-benzothiazin-3-one (1.812 g, 10 mmol), tetra-n-butylammonium bromide (0.322 g, 1 mmol), potassium carbonate (2.764 g, 20 mmol), 1-(3-chloropropyl)-4-(2-quinolylmethyl)piperazine (3.039 g, 10 mmol) and N,N-dimethylformamide (40 mℓ) was stirred for 4 days at a bath temperature of 50°C under an argon gas stream, the solvent was distilled off under reduced pressure. Water was added to the residue, followed by extraction with chloroform. The extract was washed with water and then dried over anhydrous magnesium sulfate. The extract was subjected to chromatography on a silica gel column (developer: chloroform/methanol = 100/1 to 40/1) and then crystallized from ethyl acetate, whereby 1.188 g of the title compound were obtained as yellow prisms (yield: 26.5%). m.p.: 159-161°C. 1 H-NMR(CDCl 3 )δ(ppm): 8.52(1H,s), 8.10(2H,t,J=8.8Hz), 7.80(1H,d,J=8.3Hz), 7.70(1H,td,J=7.8,1.5Hz), 7.63(1H,d,J=8.3Hz), 7.51(1H,t,J=6.8Hz), 6.86(1H,d,J=2.4Hz), 6.78(1H,d,J=8.8Hz), 6.71(1H,dd,J=8.8,2.4Hz), 3.97(2H,t,J=6.3Hz), 3.86(2H,s), 3.41(2H,s), 2.72-2.34(10H,m), 1.91(2H,q,J=6.8Hz). IR(KBr)cm -1 : 2944, 1816, 1683, 1493, 1211, 1070. Example 91 Synthesis of 8-methyl-5-{3-[4-(2-quinolylmethyl)piperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one After a mixture consisting of 5-hydroxy-8-methyl-1,2,3,4-tetrahydroquinolin-2-one (1.80 g, 10.2 mmol), tetra-n-butylammonium bromide (0.322 g, 1 mmol), potassium carbonate (4.146 g, 30 mmol), 1-(3-chloropropyl)-4-(2-quinolylmethyl)piperazine (3.67 g, 12.1 mmol) and N,N-dimethylformamide (40 mℓ) was stirred for 2 days at a bath temperature of 50°C under an argon gas stream, the solvent was distilled off under reduced pressure. Water was added to the residue, followed by extraction with chloroform. The extract was washed with water and then dried over anhydrous magnesium sulfate. The extract was subjected to chromatography on a silica gel column (developer: chloroform/methanol = 40/1) and then crystallized from ethyl acetate-n-hexane, whereby 0.773 g of the title compound was obtained as yellow leaflets (yield: 17.2%). m.p.: 150-152°C (dec.) 1 H-NMR(CDCl 3 )δ(ppm): 8.13(1H,d,J=8.8Hz), 8.10(2H,d,J=8.8Hz), 7.85-7.44(4H,m), 7.37(1H,br.s), 6.95(1H,d,J=8.3Hz), 6.50(1H,d,J=8.3Hz), 4.00(2H,t,J=6.3Hz), 3.86(2H,s), 2.95(2H,t,J=7.8Hz), 2.70-2.40(12H,m), 2.16(3H,s), 2.06-1.82(2H,m). IR(KBr)cm -1 : 3222, 2939, 2816, 1679, 1615, 1598, 1504, 1466, 1376, 1328, 1274, 1207, 1093, 838, 792, 752. Examples 92-97 In a similar manner as in Examples 90 and 91, the compounds shown in Table 10 were obtained. The compound of Example 92 was converted into its dihydrochloride salt by a method known per se in the art. Ex. Compound Name Melting point(°C) 92 3,3,7-Trimethyl-4-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 232-234 (dec.) 93 3,3,7-Trimethyl-4-{2-[4-(2-quinolylmethyl)-1-piperazinyl]ethoxy}-2,3-dihydro-1H-indol-2-one 133-135 94 7-{2-[4-(2-Quinolylmethyl)-1-piperazinyl]ethoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 171-173 (dec.) 95 8-Methyl-5-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-1,2-dihydroquinolin-2-one 170-172 96 7-{3-[4-(2-Quinolylmethyl)-1-homopiperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 130-132 97 3,3,7-Trimethyl-4-{3-[4-(2-quinolylmethyl)-1-homopiperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one 110-112 Example 98 Synthesis of 7-{1-[4-(2-quinolylmethyl)piperazinylcarbonyl]methoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one oxalate After a mixture consisting of 7-hydroxy-3,4-dihydro-2H-1,4-benzothiazin-3-one (0.544 g, 3 mmol), 1-chloroacetyl-4-(2-quinolylmethyl)piperazine (0.911 g, 3 mmol), potassium carbonate (4.146 g, 30 mmol) and N,N-dimethylformamide (40 mℓ) was stirred for 1 day at room temperature under an argon gas stream, the solvent was distilled off under reduced pressure. Water was added to the residue, followed by extraction with chloroform. The extract was washed with water and then dried over anhydrous magnesium sulfate. The extract was subjected to chromatography on a silica gel column (developer: chloroform/methanol = 50/1), whereby 0.786 g of the free base of the title compound was obtained as a yellow compound. Oxalic acid dihydrate (0.176 g, 1.4 mmol) was added to the oil (0.630 g, 1.4 mmol) and crystallization was then conducted from methanol, whereby 0.438 g of the title compound was obtained as pale yellow powder (yield: 58.1%). m.p.: 184-186°C (dec.) 1 H-NMR(CDCl 3 )δ(ppm): 8.44-8.33(1H,m), 8.12-7.54(6H,m), 6.97-6.75(2H,m), 4.83(2H,s), 4.49(2H,s), 3.97-3.80(4H,br), 3.40(2H,s), 3.33-3.17(4H,br). IR(KBr)cm -1 : 1655, 1496, 1405, 1216, 720. Example 99 Synthesis of 8-methyl-5-{1-[4-(2-quinolylmethyl) piperazinylcarbonyl]methoxy}-1,2,3,4-tetrahydroquinolin-2-one maleate In a similar manner as in Example 98, the title compound was obtained. m.p.: 184-186°C (dec.) Example 100 Synthesis of 3,3,7-trirnethyl-4-{1-[4-(2-quinolylmethyl)piperazinylcarbonyl]methoxy}-2,3-dihydro-1H-indol-2-one maleate In a similar manner as in Example 98, the title compound was obtained. m.p.: 166-168°C (dec.) Example 101 Synthesis of 3,3,7-trimethyl-4-{3-[4-(2-quinolylcarbonyl)piperazinyl]propoxy}-2,3-dihydro-1H-indol-2-one maleate A mixture consisting of 4-(chloropropoxy)-3,3,7-trimethyl-2,3-dihydro-1H-indol-2-one (0.536 g, 2 mmol) and 1-(2-quinolylcarbonyl)piperazine (1.980 g, 8 mmol) was stirred for 4 hours at a bath temperature of 150°C under an argon gas stream. The reaction mixture was allowed to cool down, and was then dissolved in chloroform. The solution was washed with water, dried over anhydrous magnesium sulfate, and then subjected to chromatography on a silica gel column (developer: chloroform/methanol = 50/1) for purification, whereby 0.943 g of the free base of the title compound was obtained as a yellow oil (yield: 100%). Maleic acid (0.232 g, 2 mmol) was added to the free base and crystallization was then conducted from ethanol, whereby 0.916 g of the title compound was obtained as white powder (yield: 77.8%). m.p.: 176-178°C (dec.) 1 H-NMR(DMSO-d 6 )δ(ppm): 10.33(1H,s), 8.54(1H,d,J=8.3Hz), 8.10-8.02(2H,m), 7.90-7.67(3H,m), 6.92(1H,d,J=9.3Hz), 6.52(1H,d,J=9.3Hz), 6.09(2H,s), 4.04(2H,t,J=5.9Hz), 3.95-2.95(10H,br), 2.14(3H,s), 2.19-2.00(2H,br), 1.32(6H,s). IR(KBr)cm -1 : 1705, 1635, 1614, 1578, 1507, 1475, 1381, 1355, 1280, 1258, 1136, 1091, 982, 868, 766. Example 102 Synthesis of 7-{3-[4-(2-quinolylcarbonyl)piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one maleate In a similar manner as in Example 101, the title compound was obtained. m.p.: 173-175°C (dec.) Example 103 Synthesis of 8-methyl-5-{3-[4-(-2-quinolylcarbonyl)piperazinyl]propoxy}-1,2,3,4-tetrahydroquinolin-2-one maleate In a similar manner as in Example 101, the title compound was obtained. m.p.: 182-184°C (dec.) Example 104 Synthesis of 7-{3-[4-(8-hydroxy-2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one dihydrochloride A 4N hydrogen chloride-ethyl acetate solution (0.45 mℓ) and a palladium-on-charcoal catalyst (90 mg) were added to a solution of 7-{3-[4-(8-benzyloxy-2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one (450 mg, 0.81 mmol) in acetic acid (6 mℓ), followed by stirring for 2 hours at a bath temperature of 80°C under a hydrogen gas stream. The catalyst was filtered off from the reaction mixture and was then washed with methanol. The filtrate and the washing were mixed, followed by concentration under reduced pressure. The residue was purified by thin-layer silica gel chromatography while using chloroform/methanol(saturated with ammonia) (15/1) as an eluent, hereby 40 mg of the free base of the title compound were obtained in a pale yellow amorphous form. The catalyst was washed further with a saturated aqueous solution of sodium hydrogencarbonate and chloroform. The chloroform layer was dried over anhydrous sodium sulfate and then concentrated, whereby 108 mg of the free base of the title compound were obtained in the form of a pale yellow amorphous (39.3% in total). This free base (148 mg) was dissolved in ethyl acetate (3 mℓ), followed by the addition of a 4N hydrogen chloride-ethyl acetate solution (0.18 mℓ) and ethanol (2 mt). The resulting mixture was stirred at room temperature for 1 hour. A precipitate was collected by filtration, whereby 168 mg of the title compound were obtained as pale brown powder (quantitative from the free base). m.p.: 263-265°C (dec.) 1 H-NMR(DMSO-d 6 )δ(ppm): 10.41(1H,s), 8.46(1H,d,J=8.5Hz), 7.61(1H,d,J=8.5Hz), 7.54-7.44(2H,m), 7.16(1H,dd,J=7.3,1.2Hz), 6.93(1H,d,J=2.7Hz), 6.90(1H,d,J=8.8Hz), 6.80(1H,dd,J=8.8,2.7Hz), 4.80(1H,br.s), 4.05(2H,t,J=6.3Hz), 3.73(2H,s), 3.42(2H,s), 2.52-2.49(10H,m), 2.23-2.14(2H,br). IR(KBr)cm -1 : 1680, 1608, 1499, 1475, 1323, 1237. Example 105 Synthesis of 7-{3-[4-(4-hydroxy-2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one In a similar manner as in Example 104, the title compound was obtained. m.p.: 205-208°C (dec.) 1 H-NMR(CDCℓ 3 -CD 3 OD)δ(ppm): 8.29(1H,d,J=8.3Hz), 7.64(1H,dd,J=7.8,7.1Hz), 7.49(1H,d,J=7.8Hz), 7.37(1H,m), 6.86-6.82(2H,m), 6.72(1H,m), 6.28(1H,s), 3.99(2H,t,J=6.1Hz), 3.57(2H,s), 3.38(2H,s), 2.75-2.49(10H,m), 1.98(2H,br). IR(KBr)cm -1 : 1672, 1632, 1606, 1496, 1473, 1233, 761. Example 106 Synthesis of 2-hydroxy-7-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one 7-{3-[4-(2-quinolylmethyl)-1-piperazinyl]propoxy}-3,4-dihydro-2H-1,4-benzothiazin-3-one-1-oxide (300 mg, 0.65 mmol) was dissolved in a mixed solvent consisting of 0.1 N hydrochloric acid (10 mℓ) and acetonitrile (10 mℓ), followed by stirring for 5 days at a bath temperature of 25°C. The reaction mixture was concentrated under reduced pressure, followed by the addition of water. The resulting mixture was washed with chloroform. The water layer was saturated with NaCl and then extracted with a 5:1 mixed solvent of chloroform and methanol. The extract was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was subjected to chromatography on a silica gel column while using chloroform-methanol (10:1) as an eluent, whereby impurities which existed at the starting point were removed. Fractions containing the target compound were collected and then concentrated under reduced pressure. The concentrate was crystallized from chloroformdiethyl ether, whereby the 203 mg of the title compound were obtained as yellow powder (67.7%). m.p.: 184-188 1 H-NMR(DMSO-d 6 )δ(ppm): 8.00-7.92(2H,m), 7.73(1H,ddd,J=7.3,6.8,1.5Hz), 7.64-7.54(2H,m), 6.96(1H,br.s), 6.92(1H,d,J=8.8Hz), 6.87(1H,d,J=2.4Hz), 6.78(1H,dd,J=8.8,2.4Hz), 5.19(1H,s), 3.95(2H,t,J=6.2Hz), 3.75(1H,s), 2.55-2.30(10H,cm,overlapped with solvent), 1.82(2H,t,J=6.8Hz). IR(KBr)cm -1 : 2955, 2814, 1672, 1498, 1229, 1046. Test 1 Antihistaminic Action and Anti-LTD 4 Action ( In vitro Tests) An isolated guinea pig ileum was cut into about 2 cm lengths. Each ileum piece was suspended in a 20-mℓ container filled with the Tyrode's buffer. An isotonic contractive response by histamine or LTD 4 was recorded on a recorder. The Tyrode's buffer was controlled at 30°C, through which a mixed gas (95%O 2 -5%CO 2 ) was bubbled. Antihistaminic action was determined by adding 10 -3 -10 -4 M histamine to an organ bath and measuring its dose-response. After the ileum piece was washed several times with the buffer, a test compound of a predetermined specific concentration was added. Subsequent to incubation for 30 minutes, the dose-response of histamine was measured again, and is presented in terms of pA 2 or pD' 2 at 10 -5 M test compound in Table 11. Antileukotrienic action was determined by investigating effects of addition of 10 -5 M test compound on a contractive response caused by 10 -8 M LTD 4 , and is presented in terms of an inhibition rate at 10 -5 M test compound in Table 11. Example Antihistaminic action (%) (10 -5 M) Anti-LTD 4 action (%) (10 -5 M) 1 8.22pA2 16 9 8.11pA2 40 26 8.01pD's 27 29 8.79pA2 48 32 8.64pA2 20 36 9.12pA2 46 39 9.08pA2 30 42 9.33pA2 13 44 8.67pA2 47 61 8.47pA2 19 69 9.42pA2 25 78 8.37pA2 27 79 8.48pA2 19 80 9.15pA2 11 81 8.04pA2 19 83 9.37pA2 26 85 8.55pA2 21 88 8.67pA2 12 89 8.55pA2 21 90 10.06pA2 16 92 8.22pA2 42 102 8.69pA2 10 Terfenadine 8.24pA2 - Test 2 H 1 Receptor Binding Inhibition Test Incubated at 37°C for 30 minutes was 1 mℓ of a 50 mM phosphate buffer (pH 7.5) which contained 0.3 nM [ 3 H]mepyramin (activity: 22 Ci/mmol), guinea pig cerebromembranous protein and a test compound. An ice-cold phosphate buffer was added to terminate the reaction, followed by immediate filtration through a Wattman CF/C filter. The filter was washed twice with 20 mℓ aliquots of the ice-cold buffer. The radioactivity of the residue was measured by a liquid scintillation counter. From a measurement value obtained without the addition of the test compound and measurements values obtained upon addition of the test compound at various concentrations, the dose-response of the inhibitory action of the test compound was measured and the 50% inhibitory concentration (IC 50 ) was determined. Using the Cheng-Prusoff formula, a dissociation constant (K D ) was calculated from the 50% inhibitory concentration (IC 50 ). In a binding assay, 10 -4 M R(-)dimethindene was used for the measurement of a nonspecific binding. From the binding assay, it was found that the receptor was of only one type and that the maximum binding (Bmax) was 278±24 fmol/mg protein. Further, the dissociation constant (K D ) of [ 3 H]mepyramin was 3.30±0.26 x 10 -9 M and when analyzed by a Hill plot, its slope was found to be 1.005. Test 3 LTD 4 Receptor Binding Inhibition Test Incubated at 22°C for 30 minutes was 0.3 mℓ of a 10 mM piperazine N,N'-bis(2-ethanesulfonate) buffer (pH 7.5) which contained 0.2 nM [ 3 H]LTD 4 , guinea pig pulmo-membranous protein and a test compound. An ice-cold tris hydrochloride/sodium chloride buffer (10 mM/100 mM, pH 7.5) was added to terminate the reaction, followed by immediate filtration through a Wattman CF/C filter. The filter was washed twice with 20 mℓ aliquots of the ice-cold buffer. The radioactivity of the residue was measured by a liquid scintillation counter. By similar methods as in the H 1 receptor test, the IC 50 of the test compound was determined and the dissociation constant (K D ) was calculated as presented in Table 12. In a binding assay, 2 µM LTD 4 was used for the measurement of a nonspecific binding. From the binding assay, it was found that the receptor was of only one type and that the maximum binding (Bmax) was 988 fmol/mg protein. Further, the dissociation constant (K D ) of [ 3 H]LTD 4 was 2.16 x 10 -10 M and when analyzed by a Hill plot, its slope was found to be 0.99. Example H1 receptor (%) LTD4 receptor (%) 1 1.73x10 -7 3.24x10 -6 9 1.35x10 -8 4.96x10 -5 26 3.63x10 -8 3.34x10 -6 36 3.49x10 -12 1.99x10 -6 41 4.32x10 -9 3.83x10 -6 45 3.39x10 -9 1.98x10 -6 50 4.57x10 -7 8.60x10 -6 54 2.49x10 -10 8.81x10 -4 60 5.45x10 -9 8.73x10 -6 61 4.69x10 -9 1.61x10 -6 75 5.58x10 -8 7.34x10 -6 77 7.45x10 -8 1.10x10 -4 78 1.82x10 -8 7.43x10 -6 79 7.59x10 -8 8.61x10 -6 80 4.31x10 -9 1.84x10 -5 85 1.83x10 -8 3.57x10 -5 90 5.01x10 -9 9.41x10 -6 92 5.57x10 -8 4.23x10 -6 93 7.10x10 -8 5.90x10 -6 97 1.87x10 -7 1.59x10 -5 Telfenadine 1.52x10 -7 - Test 4 Brain Penetration Test A brain penetration test was conducted based on the method proposed by Zang, M.Q. (J. Med. Chem., 38 , 2472-2477, 1995). Described specifically, to a mouse of 20 g to 23 g, a test compound of a given concentration was peritoneally administered. Upon elapsed time of one hour after the administration, the mouse was sacrificed. The brain tissue was taken out, and was then homogenated with a 30 mM Na,K phosphate buffer (pH 7.5) to give 40 mℓ/g wet weight. The homogenate was divided into three test tubes (900 µℓ), followed by the addition of 100 µℓ of [ 3 H]mepyramin solution (final concentration: 0.5 nM). Subsequent to incubation at 37°C for 50 minutes, an ice-cold phosphate buffer was added to terminate the reaction. Each of the resulting mixtures was immediately filtered through Wattman CF/C filter. The filter was washed twice with 20 mℓ aliquots of the ice-cold buffer. The radioactivity of the residue was measured by a liquid scintillation counter. From a measurement value obtained without administration of the test compound and measurement values obtained when the test compound were administered at respective doses, the dose-response of the inhibitory reaction by the test compound was measured to determine its 50% inhibitory dose (IC 50 ). A BP index as an index of brain penetration was calculated in accordance with the following formula: BP index = IC 50 (mg/kg)/H 1 binding inhibition dissociation constant (nM) Compound IC 50 (mg/Kg,ex vivo) BP index Ex. 90 8.5 1.7 Ex. 91 10 35.7 Ex. 92 16.5 0.29 Telfenadine 26 0.17 Capability of Exploitation in Industry The diamine derivatives (1) or salts thereof according to the present invention have antileukotrienic action and antihistaminic action in combination and are low in brain penetration, are hence useful as medicines such as asthma preventives and curatives.

Claims: A diamine derivative represented by the following formula (1) or a salt thereof: wherein R 1 represents a hydrogen atom, a hydroxyl group, an aralkyloxy group or a halogen atom; R 2 represents a hydrogen atom or a linear or branched alkyl group having 1-6 carbon atoms; A represents -C(R 3 )=CH-, R 3 being a hydrogen atom or a hydroxyl group, -CH=N-, -N(R 4 )-, R 4 being a linear or branched alkyl group having 1-6 carbon atoms or an alkoxyalkyl group, -O-, or -S-; B represents a single bond, -C(R 5 )(R 6 )-(CH 2 ) k -, R 5 and R 6 being the same or different and individually representing a hydrogen atom or a linear or branched alkyl group having 1-6 carbon atoms, and k being a value of from 0 to 2, -S(O) q CH(R 7 ), q being a value of from 0 to 2, and R 7 being a hydrogen atom or a hydroxyl group, or -CH=CH-; E represents a single bond or -(CH 2 ) 3 -; W and Y may be the same or different and individually represent -CH 2 - or -CO-; Z represents an oxygen atom or a sulfur atom; and ℓ is a value of 0 or 1, m is a value of 2 or 3, and n is a value of from 1 to 4; with the proviso that E is -(CH 2 ) 3 - when B is a single bond and E is a single bond when B is a group other than a single bond. A medicine comprising as an effective ingredient the diamine derivative or salt thereof according to claim 1. The medicine according to claim 2, which is a preventive or curative for an allergic disease. A medicinal composition comprising the diamine derivative or salt thereof according to claim 1 and a pharmaceutically acceptable carrier. Use of the diamine derivative or salt thereof according to claim 1 for the manufacture of a medicine. The use according to claim 5, wherein said medicine is a preventive or curative for an allergic disease.

Inventors: ONOGI KAZUHIRO, TAMURA MASAHIRO, TIMMERMAN HENK, TOHMA TSUTOMU, WADA YASUSHI, ZANG MINGQIANG, ONOGI, KAZUHIRO, TAMURA, MASAHIRO, TIMMERMAN, HENK, TOHMA, TSUTOMU, WADA, YASUSHI, ZANG, MINGQIANG
Applicants: KOWA CO, KOWA CO., LTD.
Application year: 1998
Main classification: C07D215
IPC codes: C07D215, C07D401, C07D417, C07D403